Brit. med. J7., 1966, 1, 80-83 Indomethacin (Indocid) is an indole-3-acetic acid derivative, which was found to have powerful anti-inflammatory and analgesic properties, and which has been under clinical investigation since October 1962. Several controlled trials demonstrated that it had some value in the treatment of rheumatic disorders, being significantly more effective than placebos in the treatment of both rheumatoid arthritis (Wanka, Jones, Wood, and Dixon, 1964) and osteoarthrosis of the hip (Wanka and Dixon, 1964) . When indomethacin was compared with phenylbutazone in a controlled trial in rheumatoid arthritis (Percy, Stephenson, and Thompson, 1964) no significant difference was noted either in terms of relief of pain or by improvement in grip-strength, but side-effects were commoner with indomethacin. All these early studies were undertaken with indomethacin in tablet form, and it was found that this preparation had disadvantages owing to variable dissolution rates of the tablets and erratic absorption from the gastro-intestinal tract. The use of capsules, available since September 1963, overcame these difficulties, and subbequent clinical experience indicated that a commensurate clinical effect could be obtained with a lower dosage of indomethacin in capsule form than when it was administered as tablets . Experience with other drugs used in the treatment of chronic rheumatic disorders, notably with the predni-steroids, has shown that potency of a drug does not establish its place as the therapeutic agent of choice. Controlled clinical trials of short duration serve to estimate the immediate value of a drug and any early side-effects, but it is only by means of long-continued clinical experience that answers may be provided to such questions as the frequency, severity, and nature of adverse sideeffects, optimum dosage levels, and the indications for or against the use of the drug. Side-effects occurred in 26 (37%) patients (Table III) , and necessitated withdrawal of treatment in 22. Inadequate clinical effect was the reason for stopping treatment in a further 15 (22%), making a total of 37 (55%) who stopped taking the drug because it was unsatisfactory. These two factors of sideeffects and poor clinical response are to some extent interdependent, as lack of benefit led in eight cases to increasing the dosage to a point where satisfactory analgesic effect was obtained only by the development of unacceptable side-effects.
Osteoerthrosis
Fifty patients suffering from osteoarthrosis were treated for periods ranging from 2 to 82 weeks, the mean duration being 28 weeks. The average daily maintenance dosage was 75 mg., the range being 25 to 125 mg. The results of treatment are shown in Table II . Only one patient was lost to follow-up through failure to attend. Of the remaining 49 patients 31 continued with treatment, and to these may be added the three patients who obtained a complete remission of symptoms, making a total of 34 (69%) in whom the outcome was regarded as completely or reasonably successful.
The patients' estimate of benefit was based upon the factors of pain relief, reduction of stiffness, improvement in functional capacity, and comparison with previous therapy. By these criteria 28 (56%) patients thought that indomethacin was satisfactory, 14 (28%) found it to be fairly good, and only 8 (16%) considered it to be relatively or absolutely ineffective.
Side-effects occurred in 14 (28%) patients and were responsible for the withdrawal of the drug in 11. The incidence of side-effects was lower than in the rheumatoid group, but not significantly so. The number of patients withdrawn because of inadequate effect was much lower in the osteoarthrotic patients (8%) than in those suffering from rheumatoid disease (22%), and this difference was statistically significant (X2 = 4, P<0.05).
When the outcome of therapy was compared there was a significantly favourable result for the osteoarthrotic group in comparison with the rheumatoid patients (X2 = 6, P<0.02). Furthermore, when the patient's estimate of benefit was considered, the numbers claiming satisfactory benefit were significantly higher in the osteoarthrotic group (x2 = 10, P<0.005).
Miscellaneous Group
The composition of this group of 17 patients is shown in Table I , and these patients received treatment for periods ranging from 1 to 55 weeks, the mean being 13 weeks. The average dosage was 87 mg. daily, the range being 50 to 150 mg. Seven patients experienced side-effects compelling withdrawal of the drug in six cases, and in a further two it was withdrawn because of inadequate benefit. Two patients stopped taking indomethacin when they left the district, and in three the drug was stopped because of satisfactory remission of symptoms. Four patients continued to take indomethacin. The numbers involved are too small to permit detailed analysis of the results in the group as a whole or in the various diagnostic subgroups, but some observations on the outcome are presented.
Of the two patients suffering from psoriatic arthritis, one improved and continued with treatment but the other developed side-effects within two weeks and had to stop. A similar response was observed with the two patients suffering from polymyalgia rheumatica, one of whom developed side-effects, while the other found indomethacin to be effective and was able to stop steroid therapy. None of the three patients with cervical spondylosis obtained striking benefit, but all had complicating illnesses and had been refractory to previous drugs and physiotherapy.
Four patients suffering from ankylosing spondylitis were treated and three had to discontinue because of side-effects, the therapeutic response being rated as satisfactory, good, and slight respectively. The fourth patient continued treatment with satisfactory effect. The side-effects could be classified in three main groups, which, in order of frequency, were neurological, gastrointestinal, and dermatological. The commonest symptom was headache, which was variable in its severity, character, and distribution and was not associated with any apparent vascular changes. Most frequently the headache was located centrally in the skull or at the vertex and occurred on first waking or shortly after the first capsule of the day had been taken. In the majority of cases the headache was associated with vertigo, light-headedness, or a feeling of slight confusion. In the most severe cases there was associated nausea, malaise, and vomiting, variously described as motion-sickness or moderate inebriation. When the headache was slight it was possible to avoid it by temporary reduction of the dosage, and five patients were able to continue treatment after this had been done. Seven anti-inflammatory drugs, took indomethacin tablets for 14 weeks and then capsules for 26 weeks before she had a slight melaena. As indomethacin gave such symptomatic relief she later tried suppositories but was unable to retain these. Three patients developed a diffuse erythematous macular rash, associated with mild stomatitis in one case. In all cases the rash cleared within a day of discontinuing treatment. One of these patients resumed taking indomethacin on her own initiative but stopped it when the rash occurred within a few days. Possible, but not proved, side-effects included (a) the occurrence of furunculosis in two men, which cleared while they continued with indomethacin; (b) the aggravation of leg oedema in two women, both of whom were receiving steroid therapy, and (c) the aggravation of pre-existing mild diabetes in a man. BRmTsH MEDSCALJOURNA.
Discussion
It is clear from reported clinical experience that indomethacin is a powerful compound, capable of giving relief of symptoms and reduction of inflammatory signs in several rheumatic disorders. The most striking reduction of inflammatory signs has been noted in gout and in acute articular exacerbations of rheumatoid disease. However, the greatest benefit has been obtained in osteoarthrosis, particularly when the hip-joints were involved. The results of treatment were significantly better in the osteoarthrotic than in the rheumatoid group when judged by the criteria of (a) fewer failures owing to lack of effect, (b) numbers of patients able to continue with satisfactory relief of symptoms without experiencing side-effects, and (c) the patients' own estimates of benefit.
Of the total group of 137 patients 39 (28%) had to stop treatment because of unacceptable side-effects and 21 (15%) because of lack of benefit, while six patients stopped treatment for other reasons. Nine patients stopped because of satisfactory remission and 62 continued to take the drug, making 71 (52%) in whom the outcome has been satisfactory. This proportion of success must be judged against the background of the previous history of these patients, as no patient was treated with indomethacin ab initio but only when they presented a therapeutic problem. Thus all 70 rheumatoid patients had received aspirin, 35 had been given oral predni-steroid therapy, and 44 had been treated with one or more anti-inflammatory preparaiions-for example, phenylbutazone, gold salts, or chloroquine preparations. In the miscellaneous group of 17 patients 14 had received aspirin, 5 oral predni-steroids, and all 17 had taken other anti-inflammatory preparations, mainly phenylbutazone. In the group of 50 patients suffering from osteoarthrosis the previous therapy had comprised aspirin in 48 cases, oral prednisteroid therapy in 5, and other anti-inflammatory drugs in 40.
In these circumstances the results obtained indicate that indomethacin has provided a most useful additional therapy in the management of osteoarthrosis, gout, and some patients suffering from rheumatoid arthritis. Although in our experience gout treated by capsules of indomethacin has been limited to three cases, the results obtained in these patients, supplemented by our experience with three patients treated by tablets, fully confirm the beneficial effects recorded by Hart and Boardman (1963) (Percy et al., 1964 arthritis, particularly with actively inflamed large joints, and ankylosing spondylitis. The fact that indomethacin is a rapidly effective, non-steroidal, anti-inflammatory agent, like phenylbutazone, makes it a useful alternative to predni-steroid therapy. As with many other drugs used in the treatment of chronic rheumatic disorders, indomethacin causes undesired effects which are particularly apt to occur in the early stages of treatment. Fortunately most of these are trivial and clear rapidly after withdrawal of the drug. In view of the occurrence of severe neurological disturbance in seven of our cases we feel that it would be unwise to ignore and dangerous to suppress the headache and associated symptoms so commonly encountered. If these cannot be avoided by gradual induction or by subsequent reduction of dosage, they must be taken as an indication for stopping the drug. It would seem reasonable to insist that indomethacin should only be given with caution to any patient with a history of depressive illness. Active or recent peptic ulceration should be regarded as an absolute contraindication, and therapy should not be resumed in any patient who exhibits a rash during treatment.
Summary
Clinical experience with indomethacin during a period of 18 months in a series of 137 patients comprising 70 with rheumatoid arthritis, 50 with osteoarthrosis, and 17 with miscellaneous rheumatic disorders is recorded. A progressive dosage regime was used beginning with 25 mg. daily, and the average daily maintenance dosage was 75 mg.
Striking benefit was obtained in osteoarthrosis with a satisfactory outcome of treatment in 69 % of cases, which was significantly better than the rheumatoid group where 44% were satisfactory.
An excellent response was also seen in three patients suffering from acute gout.
A total of 70 side-effects occurred in 47 patients and compelled withdrawal of treatment in 39 (28% of the total group). The principal undesired symptoms were headache associated with vertigo, etc., but major neurological disturbance occurred in seven cases. All these symptoms subsided rapidly on withdrawal of therapy. There was one instance of slight melaena, one perforated ulcer, and three rashes developed during therapy.
Indomethacin is thought to be a useful addition to the range of drugs used in the management of certain rheumatic disorders, notably in osteoarthrosis, acute gout, rheumatoid arthritis, and spondylitis.
of infants (Wallman and Hilton, 1962) , ampicillin, which has been proved to be effective in certain respiratory disorders in children (Elliot, Stokes, and Maxwell, 1964) , was chosen.
Patients, Materials, and Methods An epidemic of bronchiolitis occurred in Belfast in November 1964. The criteria of selection for the trial were coryza, paroxysmal cough, expiratory wheeze, and increased respiratory rate. All patients except three had fine crepitations at the lung bases and were sufficiently distressed to be using the accessory muscles of respiration. The progress of each case was reported daily on a special chart which listed pulse rate, temperature, respiratory rate, the use of accessory muscles of respiration, expiratory wheeze, adventitious sounds in the chest, and the presence of cyanosis.
The treatment consisted of ampicillin or placebo 125 mg. six-hourly, all children received ephedrine 1 gr. (16 mg.) thrice daily, and most of them were nursed for a day or two in an oxygen tent with aerosol water vapour. One or other treatment was allocated to the children according to a randomized code. It was decided that patients who became dangerously ill owing to steady deterioration of their condition should be given an antibiotic and removed from the trial. This was a difficult
